Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 18, Pages 5679-5684
Publisher
Proceedings of the National Academy of Sciences
Online
2015-04-21
DOI
10.1073/pnas.1418962112
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
- (2015) Avi Ashkenazi JOURNAL OF CLINICAL INVESTIGATION
- Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
- (2014) Jonathan D. Graves et al. CANCER CELL
- Death receptor agonist therapies for cancer, which is the right TRAIL?
- (2013) Pamela M. Holland CYTOKINE & GROWTH FACTOR REVIEWS
- Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties
- (2013) O. Seifert et al. MOLECULAR CANCER THERAPEUTICS
- APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors
- (2013) C. Gieffers et al. MOLECULAR CANCER THERAPEUTICS
- BH3 Mimetics: Status of the Field and New Developments
- (2013) C. Billard MOLECULAR CANCER THERAPEUTICS
- Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
- (2013) Diego De Miguel et al. MOLECULAR PHARMACEUTICS
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
- (2012) Nicholas S. Wilson et al. CANCER CELL
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
- (2012) V. Subbiah et al. MOLECULAR CANCER THERAPEUTICS
- TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer
- (2012) Francois Gonzalvez et al. MOLECULAR CELL
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy
- (2011) Ming-Kung Yeh et al. International Journal of Nanomedicine
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Using patterned supported lipid membranes to investigate the role of receptor organization in intercellular signaling
- (2011) Pradeep M Nair et al. Nature Protocols
- Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
- (2010) Annie Yang et al. CURRENT OPINION IN CELL BIOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Restriction of Receptor Movement Alters Cellular Response: Physical Force Sensing by EphA2
- (2010) K. Salaita et al. SCIENCE
- Death receptor signal transducers: nodes of coordination in immune signaling networks
- (2009) Nicholas S Wilson et al. NATURE IMMUNOLOGY
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now